NASDAQ:MYGN - Myriad Genetics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $42.02 -0.67 (-1.57 %) (As of 07/16/2018 04:00 PM ET)Previous Close$42.69Today's Range$40.79 - $42.4752-Week Range$23.28 - $44.31Volume685,200 shsAverage Volume735,576 shsMarket Capitalization$2.98 billionP/E Ratio39.13Dividend YieldN/ABeta0.47 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. Receive MYGN News and Ratings via Email Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:MYGN CUSIP62855J10 Webwww.myriad.com Phone801-584-3600 Debt Debt-to-Equity Ratio0.07 Current Ratio3.52 Quick Ratio3.16 Price-To-Earnings Trailing P/E Ratio39.13 Forward P/E Ratio34.73 P/E Growth3.24 Sales & Book Value Annual Sales$771.40 million Price / Sales3.81 Cash Flow$1.7443 per share Price / Cash24.09 Book Value$11.42 per share Price / Book3.68 Profitability EPS (Most Recent Fiscal Year)$1.05 Net Income$21.80 million Net Margins17.67% Return on Equity9.52% Return on Assets6.82% Miscellaneous Employees2,400 Outstanding Shares69,910,000Market Cap$2,984.33 Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions What is Myriad Genetics' stock symbol? Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN." How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday, May, 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.04. The business earned $193.50 million during the quarter, compared to analysts' expectations of $188.22 million. Myriad Genetics had a return on equity of 9.52% and a net margin of 17.67%. The firm's quarterly revenue was down 1.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.27 earnings per share. View Myriad Genetics' Earnings History. What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $1.19-1.21 for the period, compared to the Thomson Reuters consensus estimate of $1.15. The company issued revenue guidance of $771-773 million, compared to the consensus revenue estimate of $770.43 million. What price target have analysts set for MYGN? 10 brokers have issued 12 month price targets for Myriad Genetics' shares. Their predictions range from $23.00 to $55.00. On average, they expect Myriad Genetics' stock price to reach $35.30 in the next twelve months. This suggests that the stock has a possible downside of 16.0%. View Analyst Ratings for Myriad Genetics. What is the consensus analysts' recommendation for Myriad Genetics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Myriad Genetics stock? Here are some recent quotes from research analysts about Myriad Genetics stock: 1. According to Zacks Investment Research, "Despite weakness in Hereditary Cancer testing revenues, Myriad Genetics exited the third quarter of fiscal 2018 on a promising note. The company observed strong growth in GeneSight, Vectra DA and Prolaris testing revenues. Also, Hereditary Cancer volumes expansion was impressive. Furthermore, we are upbeat about the company seeing growth in new product volumes and success of its Elevate 2020 program. Moreover, the company's latest receipt of manufacturing and marketing approval for its BRACAnalysis Diagnostic System in Japan, buoys optimism. Further, the raised FY18 guidance instills confidence in investors. Accordingly, over the past three months, the company has outperformed its industry. However, the decline in Hereditary cancer testing revenues due to price reductions in long-term contracts, raises a concern. Additionally, currency fluctuations and stiff competition are major headwinds." (5/18/2018) 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018) Who are some of Myriad Genetics' key competitors? Some companies that are related to Myriad Genetics include Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER). Who are Myriad Genetics' key executives? Myriad Genetics' management team includes the folowing people: Mr. Mark Christopher Capone, Pres, CEO & Director (Age 56)Mr. R. Bryan Riggsbee, CFO & Treasurer (Age 47)Dr. Jerry S. Lanchbury Ph.D., Chief Scientific Officer (Age 59)Mr. Richard M. Marsh Esq., Exec. VP, Gen. Counsel & Sec. (Age 60)Mr. Alexander Ford, Pres of Myriad Genetic Laboratories, Inc. (Age 51) Has Myriad Genetics been receiving favorable news coverage? News articles about MYGN stock have been trending somewhat positive on Monday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myriad Genetics earned a coverage optimism score of 0.16 on Accern's scale. They also assigned media stories about the company an impact score of 43.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are Myriad Genetics' major shareholders? Myriad Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.17%) and Bank of Montreal Can (0.10%). Company insiders that own Myriad Genetics stock include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics. Which institutional investors are selling Myriad Genetics stock? MYGN stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics. Which institutional investors are buying Myriad Genetics stock? MYGN stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics. How do I buy shares of Myriad Genetics? Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Myriad Genetics' stock price today? One share of MYGN stock can currently be purchased for approximately $42.02. How big of a company is Myriad Genetics? Myriad Genetics has a market capitalization of $2.98 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.05 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe. How can I contact Myriad Genetics? Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected] MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)Community Ranking: 1.9 out of 5 ()Outperform Votes: 312 (Vote Outperform)Underperform Votes: 521 (Vote Underperform)Total Votes: 833MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?